Lipocine
LPCN
54 hedge funds and large institutions have $26.2M invested in Lipocine in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
21% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.46M
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2% more funds holding
Funds holding: 53 → 54 (+1)
72% less capital invested
Capital invested by funds: $95.2M → $26.2M (-$69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.64M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.62M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
+$2.18M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.71M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$9.18M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$3.75M |
| 3 |
RI
RTW Investments
New York
|
-$2.44M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.27M |
| 5 |
RA
Royce & Associates
New York
|
-$1.67M |
LPCN Hedge Fund Activity: Q2 2016 in Review
54 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2016, worth a combined $26.2M — down 72% from $95.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LPCN positions and 20 closed out — a net gain of 2 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.64M. The largest seller was Visium Asset Management, exiting entirely with an estimated $9.18M sold.
- 54 institutional investors held Lipocine (LPCN) as of Q2 2016, up from 53 in Q1 2016.
- Funds reported $26.2M of Lipocine stock for Q2 2016, down 72% quarter-over-quarter.
- 22 funds opened new Lipocine positions in Q2 2016 and 20 closed out, a net change of +2 holders.
- The largest Lipocine buyer in Q2 2016 was Armistice Capital, an estimated $3.64M added.
- The largest Lipocine seller in Q2 2016 was Visium Asset Management, an estimated $9.18M sold.
Based on aggregated 13F filings for Q2 2016.